

# NEAUVIA®

## PRESS RELEASE

### Neauvia's achievement at AMWC 2024 Awards in Monaco

**Monaco, March 27th, 2024** – Neauvia is honoured to announce its distinguished success at the **AMWC 2024 Awards** held in Monaco. The company proudly received the "**Best Injectable Dermal Filler**" award for its groundbreaking product, **STIMULATE, the only PEG-HA + CaHA** filler.

The AMWC Awards, internationally renowned for their commitment to acknowledging innovation and excellence in the global medical aesthetic market, spotlighted Neauvia as a leader in the category of Injectable Dermal Fillers.

Winners were announced at AMWC Congress on March 27th, 2024. This prestigious international recognition, conferred by a panel of esteemed jurors and open for voting by all professionals in the Aesthetic Medicine Community, reaffirms Neauvia's dedication to rethinking medical aesthetics.

*"We are proud to receive this renowned award and acknowledgment. These achievements highlight Neauvia's Red Team dedication and our commitment to innovation in the Medical Aesthetics landscape." stated Gabriele Drigo, founder and CEO of Neauvia.*

### **STIMULATE stands out as the only PEG-HA + CaHA Filler in the market.**

It is a groundbreaking injectable made of Hyaluronic Acid (HA) cross-linked with PEG, enriched with Glycine, L-Proline and Calcium Hydroxyapatite (CaHA).

Its advanced formulation has been demonstrated to effectively address skin and subcutaneous tissue concerns, in particular, the correction of disorders and the correction of mid-face volume deficit. [Ref1] The collected data highlight an efficient mechanical effect of the PEGylated polymeric acid matrix enriched with CaHA, aligning with other evidence in vitro and in vivo. [Ref1]

*"Through STIMULATE, Neauvia showcases its continuous dedication to pioneering R&D and medical excellence. Trusted by thousands of doctors worldwide, STIMULATE epitomizes Neauvia's commitment, delivering patient satisfaction with its safety and efficacy." Professor Nicola Zerbinati, Dermatologist and Neauvia Chief Scientific Officer*

Neauvia remains steadfast in its mission to lead the Medical Aesthetics industry with cutting-edge products and unwavering commitment to enhancing healthcare practitioners' capabilities worldwide.

Discover more about our award-winning product "Stimulate" and explore techniques and feedback from industry peers on [Neuviachannel.com](https://neuviachannel.com).

For media inquiries, please contact: [info@neauvia.com](mailto:info@neauvia.com)

# NEAUVIA®

## **About Neauvia:**

Neauvia aims to inspire and shape the world of aesthetic medicine, opening up new lifestyles and creating a community that embraces its new concept of aesthetics.

Created in 2012, distributed in more than 80 countries worldwide, Neauvia is a high growth multinational corporation pioneer in medical aesthetics with Headquarter in Geneva, production sites in Italy and Poland and subsidiaries in Italy, Switzerland, France, Spain, Poland, Germany, UK and regional offices in US, Dubai, Sao Paulo and Singapore.

Thanks to a comprehensive range of high-end technologies working in synergy, it delivers safe and more effective results for facial, body and intimate rejuvenation. Rethinking medical aesthetics as premium experiences, by fully integrating this approach into a modern and healthy lifestyle, Neauvia empowers all beauty lovers.

Neauvia is built on three pillars: disruptive (opening new communication territories), science-based (expertise backed by science) and Lifestyle (creating desirability).

## **Legal mentions and references :**

Stimulate is class III medical device is regulated under the EU MDR 2017/745 Regulation. Manufacturer: MATEX LAB SPA, via Carlo Urbani 2 ang. via Enrico Fermi, Brindisi, Italy. Please carefully read the instructions in the leaflets. The use of these products requires the intervention of a healthcare professional. Only to be used by physicians in accordance with local legislation, trained in the injection techniques on Hyaluronic Acid based fillers.

1. Zerbinati N, D'Este E, De Silvestri A, Zullino M, Rabbiosi G, Guida S, Kubik P, Stabile G, Mocchi R, Barlusconi C et al. Efficacy of Pegylated Hyaluronic Acid filler enriched with Calcium Hydroxyapatite: a 24-week post-market, observational, prospective, open-label, single-center study. J. Funct. Biomater. 2023, 14, 345. <https://doi.org/10.3390/jfb14070345>.